Malaria: Difference between revisions
From WikiDemocracy
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 163: | Line 163: | ||
[https://www.sciencedirect.com/science/article/pii/S0140673623025114 by Mehreen S Datoo DPhil 16/2/24 ScienceDirect] | [https://www.sciencedirect.com/science/article/pii/S0140673623025114 by Mehreen S Datoo DPhil 16/2/24 ScienceDirect] | ||
Recently, we found that a new malaria vaccine, R21/Matrix-M, had over 75% efficacy against clinical malaria with seasonal administration in a phase 2b trial in Burkina Faso. Here, we report on safety and efficacy of the vaccine in a phase 3 trial enrolling over 4800 children across four countries followed for up to 18 months at seasonal sites and 12 months at standard sites. | Recently, we found that a new malaria vaccine, R21/Matrix-M, had over 75% efficacy against clinical malaria with seasonal administration in a phase 2b trial in Burkina Faso. Here, we report on safety and efficacy of the vaccine in a phase 3 trial enrolling over 4800 children across four countries followed for up to 18 months at seasonal sites and 12 months at standard sites. | ||
=====A malaria vaccine for travelers and military personnel: Requirements and top candidates===== | |||
[https://www.sciencedirect.com/science/article/pii/S0264410X15014139 by Nimfa Teneza-Mora ScienceDirect] | |||
Malaria remains an important health threat to non-immune travelers with the explosive growth of global travel. Populations at high risk of acquiring malaria infections include once semi-immune travelers who visit friends and relatives, military forces, business travelers and international tourists with destinations to sub-Saharan Africa, where malaria transmission intensity is high. | |||
